The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease
Drug Discoveries & Therapeutics · 30.06.2025 · 19 (3) · 208-209
DOI: 10.5582/ddt.2025.01055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Discoveries & Therapeutics, erschienen am 30.06.2025. Verfasst von Shasha Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Peptide Fragments, tau Proteins. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Anesthesiology, Weihai Central Hospital Affiliated to Qingdao University, Weihai, Shandong, China.
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Zitieren
APA
Hu, S., Yu, H., & Gao, J. (2025). The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease. Drug Discoveries & Therapeutics, 19(3), 208-209. https://doi.org/10.5582/ddt.2025.01055
Vancouver
Hu S, Yu H, Gao J. The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease. Drug Discoveries & Therapeutics. 2025;19(3):208-209. doi:10.5582/ddt.2025.01055
BibTeX
@article{Hu2025,
author = {Hu, Shasha and Yu, Haizhou and Gao, Jianjun},
title = {The pTau217/Aβ1-42 plasma ratio: The first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease},
journal = {Drug Discoveries & Therapeutics},
year = {2025},
volume = {19},
number = {3},
pages = {208--209},
doi = {10.5582/ddt.2025.01055}
}
EUVIMED